c-Kit

SCFR;CD117



c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.

c-Kit Inhibitors & Modulators

AC710

Cat. No.: HY-13493

Bioactivity: AC710 is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Bioactivity: Amuvatinib (MP470) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits **c-Kit (D816V)**, **c-Kit (D816H)**, **c-Kit (V560G)**, **c-Kit (V654A)**, **PDGFRα (D842V)**, and **PDGFRα (V561D)** with IC_{50}s of 950 nM, 10 nM, 34 nM, 127 ...

Purity: 99.36%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Bioactivity: Amuvatinib hydrochloride (MP470 hydrochloride) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits **c-Kit (D816V)**, **c-Kit (D816H)**, **c-Kit (V560G)**, **c-Kit (V654A)**, **PDGFRα (D842V)**, and **PDGFRα (V561D)** with IC_{50}s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively...

Purity: >98%
Clinical Data: No Development Reported
Size:



AST 487

(NVP-AST 487)

Cat. No.: HY-15002

Bioactivity: AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.

Purity: 98.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Avapritinib

(BLU-285)

Cat. No.: HY-101561

Bioactivity: Avapritinib is a potent and selective exon 17 mutant **KIT kinase** inhibitor with IC_{50} of 0.27 nM for **KIT D816V**.

Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD2932

Cat. No.: HY-18179

Bioactivity: AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.

Purity: 98.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AZD3229

Cat. No.: HY-112802

Bioactivity: AZD3229 is a potent pan- **KIT** mutant inhibitor for the treatment of gastrointestinal stromal tumors.

Purity: 99.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD3229 Tosylate

Cat. No.: HY-112802A

Bioactivity: AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

Purity: 98.54%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



c-Kit-IN-1

Cat. No.: HY-15240

Bioactivity: c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with IC_{50}s of <200 nM.

Purity: 98.46%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Bioactivity: Cabozantinib is a potent multiple receptor tyrosine kinases inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Tel: 4008203792 Fax: 021-53700325 Email: sales@MedChemExpress.cn

Dovitinib

(CHIR-258; TKI258) Cat. No.: HY-50905

Bioactivity: Dovitinib is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.

Purity: 99.31%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Flumatinib

(HHGV678) Cat. No.: HY-13904

Bioactivity: Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively. IC50 Value: 1.2 nM (c-Abl); 307.6 nM(PDGFRβ); 2662 nM (c-Kit) [1] Target: c-Abl; c-Kit; PDGRFβ in vitro: HH-GV-678 can predominantly inhibit the autophosphorylation of...

Purity: 99.94%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Bioactivity: Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively. IC50 Value: 1.2 nM (c-Abl); 307.6 nM(PDGFRβ); 2662 nM (c-Kit) [1] Target: c-Abl; c-Kit; PDGRFβ in vitro:...

Purity: 95.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water,
500 mg



Imatinib

(STI571) Cat. No.: HY-15463

Bioactivity: Imatinib is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (**IC_{50}**=100 nM) tyrosine kinases.

Purity: 99.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
200 mg, 500 mg, 1 g, 5 g



Imatinib Mesylate

(CGP-57148B; STI-571) Cat. No.: HY-50946

Bioactivity: Imatinib Mesylate is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (**IC_{50}**=100 nM) tyrosine kinases.

Purity: 99.90%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
100 mg, 200 mg, 500 mg, 1 g, 5 g

ISCK03

Cat. No.: HY-101443

Bioactivity: ISCK03 is a specific **SCF/c-Kit** inhibitor.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Masitinib

(AB1010) Cat. No.: HY-10209

Bioactivity: Masitinib is an orally available **Kit** inhibitor with an **IC_{50}** of 200 nM. It also inhibits **PDGFRα/β** with an **IC_{50}** of 540 nM/800 nM nM.

Purity: 99.70%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg



Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Bioactivity: Masitinib mesylate is a novel inhibitor for **Kit** and **PDGFRα/β** with **IC_{50}** of 200 nM and 540 nM/800 nM, and has weak inhibition to ABL and c-Fms.

Purity: 99.31%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg



Motesanib

(AMG 706;) Cat. No.: HY-10228

Bioactivity: Motesanib is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with **IC_{50}**s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.

Purity: 99.75%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Motesanib Diphosphate

(Motesanib; AMG 706) Cat. No.: HY-10229

Bioactivity: Motesanib Diphosphate is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with **IC_{50}**s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.

Purity: 99.64%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



OSI-930

Cat. No.: HY-10204

Bioactivity: OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. IC50 value: 9 nM(VEGFR2); 15 nM(CSF1R); 80 nM (Kit activated) [1] Target: VEGFR2/Kit/CSF1R in vitro: OSI-930...

Purity: 97.23%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Pazopanib (GW786034)

Cat. No.: HY-10208

Bioactivity: Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with **IC_{50}**s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.68%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Pazopanib Hydrochloride (GW786034)

Cat. No.: HY-12009

Bioactivity: Pazopanib Hydrochloride is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an **IC_{50}** of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.92%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Pexidartinib (PLX-3397)

Cat. No.: HY-16749

Bioactivity: Pexidartinib (PLX-3397) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 13 nM, 27 nM, and 11 nM for **CSF1R**, **c-Kit**, and **FLT3**, respectively.

Purity: 99.23%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



PLX647

Cat. No.: HY-13838

Bioactivity: PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively. IC50 value: 28/16 nM(FMS/KIT) [1] Target: FMS/KIT dual inhibitor in vitro: PLX647 was tested against a panel of 400 kinases at a concentration of 1 μM, 35-fold above its FMS enzymatic IC50 and 60-fold above its KIT...

Purity: 98.20%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Ripretinib (DCC-2618)

Cat. No.: HY-112306

Bioactivity: Ripretinib (DCC-2618) is a pan- **KIT** and **PDGFRA** inhibitor, and has antitumor activity.

Purity: 99.46%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Sitravatinib (MGCD516; MG516)

Cat. No.: HY-16961

Bioactivity: Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/L

Purity: 98.64%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Sorafenib (Bay 43-9006)

Cat. No.: HY-10201

Bioactivity: Sorafenib (Bay 43-9006) is a potent multikinase inhibitor with **IC_{50}**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.

Purity: 99.92%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg



Sorafenib Tosylate (Bay 43-9006)

Cat. No.: HY-10201A

Bioactivity: Sorafenib tosylate is a potent multikinase inhibitor, with **IC_{50}**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.

Purity: 99.53%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg



SU14813

Cat. No.: HY-10501

Bioactivity: SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with **IC_{50}**s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.

Purity: 95.74%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



SU14813 maleate

Cat. No.: HY-10501A

Bioactivity: SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with **IC_{50}**s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



Telatinib

(Bay 57-9352)

Cat. No.: HY-10527

Bioactivity: Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with **IC_{50}**s of 6, 4, 15 and 1 nM, respectively.

Purity: 99.49%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg